Cis-platinum: a new anticancer agent.

Williams, Christopher J.; Whitehouse, J. M. A.

doi:10.1136/bmj.1.6179.1689

Cited by 90 publications

(27 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Platinum agents are main chemotherapeutic agents used in the treatment of cancers (Williams and Whitehouse, 1979). As mentioned, ES cell-specific miRs have a central role in G 1 -S transition and promotion of cel- (0,015 and 0,014),LATS2 siRNA (0,079 and 0,058),057 and 0,025) mutant and wild-type respectively.…”

Section: Cisplatin Sensitivity In Gcc and Proposed Model For Involvemmentioning

confidence: 99%

Role of stem cell proteins and microRNAs in embryogenesis and germ cell cancer

Eini¹,

Dorssers²,

Looijenga³

2013

Int. J. Dev. Biol.

View full text Add to dashboard Cite

show abstract

Section: Cisplatin Sensitivity In Gcc and Proposed Model For Involvemmentioning

confidence: 99%

Role of stem cell proteins and microRNAs in embryogenesis and germ cell cancer

Eini¹,

Dorssers²,

Looijenga³

2013

Int. J. Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…The antineoplastic action mechanism is associated to the selective and persistent inhibition of the deoxyribonucleic acid synthesis (DNA) 3 . Its side effects include ototoxicity, kidney toxicity, medullar suppression and gastrointestinal disorders 4 .…”

Section: Introductionmentioning

confidence: 99%

The role of apoptosis in cisplatin-induced ototoxicity in rats

Freitas¹,

Figueiredo²,

Brito³

et al. 2009

Braz. j. otorhinolaryngol. (Impr.)

View full text Add to dashboard Cite

Ci splatin is a chemotherapy agent frequently used to treat different types of neoplasia. Ototoxicity is one of the side-effects which cause significant morbidity and limits its use. This study aimed at assessing the role of apoptosis in cisplatin-induced ototoxicity. Design: experimental study. Materials and Methods: male Wistar rats were treated with intraperitoneal cisplatin, in the doses of 24 and 16 mg/kg. The animals were assessed by means of distortion product evoked otoacoustic emissions (DPEOAE) or brainstem evoked auditory potentials (BEAP) in the third (D3) and fourth (D4) days after drug infusion onset. Following that, their cochleas were removed for immunohistochemical studies of apoptosis -TUNEL method. Results: the group treated with 24 mg/kg showed a significant reduction in DPEOAE amplitude, and such fact was not seen with the 16 mg/kg. Both doses caused an increase in BEAP electrophysiological threshold in D3 and D4. Apoptosis was the injury mechanism responsible for the cisplatin-induced ototoxicity -16 mg/kg dose, when the animals were assessed on D3. Conclusion: apoptosis may be involved in the cisplatin-induced ototoxicity, depending on the dose and time of injury assessment.

show abstract

“…Introduction m-Diamminedichloroplatinum (CDDP) is now be ing used frequently as an antitumour agent [1,2], but its usefulness is sometimes limited by nephrotoxicity. Although the nephrotoxicity of CDDP has been well documented during and shortly after administration [3,4], reports on long-term renal effects of prolonged platinum therapy are not available.…”

mentioning

confidence: 99%

Influence of Combination Chemotherapy with <i>cis</i>-Diamminedichloroplatinum on Renal Function: Long-Term Effects

et al. 1983

View full text Add to dashboard Cite

Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were determined in 8 patients with disseminated testicular carcinoma before, during and 1 year after termination of a combination chemotherapy with cis-diamminedichloroplatinum (CDDP). The decrease in median GFR in comparison with the pretreatment value was 15.5% at the start of the maintenance therapy, 23% at the end of the maintenance therapy and 15.5% 1 year after termination of therapy. The comparable reduction in ERPF at those instants was 15.5, 19 and 23.5%, respectively. At all intervals the changes in GFR were significantly reduced in comparison with pretreatment values. No significant change in both GFR and ERPF was found either during or after discontinuation of maintenance treatment. The fall in ERPF was significant during the total period of treatment as well as during the total time of observation. Thus, no cumulative nephrotoxicity during therapy, nor improvement in renal function thereafter was found. Serum levels of creatinine and beta-2-microglobulin did not express the changes in renal function.

show abstract

Cis-platinum: a new anticancer agent.

Cited by 90 publications

References 14 publications

Role of stem cell proteins and microRNAs in embryogenesis and germ cell cancer

Role of stem cell proteins and microRNAs in embryogenesis and germ cell cancer

The role of apoptosis in cisplatin-induced ototoxicity in rats

Influence of Combination Chemotherapy with <i>cis</i>-Diamminedichloroplatinum on Renal Function: Long-Term Effects

Contact Info

Product

Resources

About